Trevi Therapeutics Stock (NASDAQ:TRVI)

Forecast Ownership Financials Chart Transcripts

Previous Close

$9.62

52W Range

$2.36 - $9.92

50D Avg

$7.29

200D Avg

$5.67

Market Cap

$1.19B

Avg Vol (3M)

$2.05M

Beta

0.72

Div Yield

TRVI Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

May 07, 2019

Website

TRVI Performance

TRVI Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-51.52M	$-33.92M	$-29.91M
Net Income	$-47.91M	$-29.07M	$-29.15M
EBITDA	$-51.52M	$-33.80M	$-29.86M
Basic EPS	$-0.47	$-0.29	$-0.45
Diluted EPS	$-0.47	$-0.29	$-0.45

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 08, 25 | 4:30 PM

Q1 25May 11, 25 | 4:30 PM

Q4 24Mar 18, 25 | 4:30 PM

Peer Comparison

Ticker	Company
KZR	Kezar Life Sciences, Inc.
LYRA	Lyra Therapeutics, Inc.
VRCA	Verrica Pharmaceuticals Inc.
VINC	Vincerx Pharma, Inc.
BCAB	BioAtla, Inc.
APLT	Applied Therapeutics, Inc.
STTK	Shattuck Labs, Inc.